Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECSMOKE
2024-518135-10-00Phase 3Suspended
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varenicline and nicotine in nicotine dependence (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Continuous smoking abstinence rate during the last 4 weeks of a treatment period of 3 months. Started Sep 2026; status: suspended.
02
Drugs
vareniclinenicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2024-518135-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518135-10-00.